Damora Therapeutics is trading at $21.64, up 5.25%, alongside a broadly higher market, though no specific catalyst for the shares has been identified. - No October 9 company-specific announcement explaining the gain surfaced; the latest identified company release was October 2, concerning employee inducement grants. - The S&P 500 is up 0.60%, the Nasdaq 0.62%, the Dow 0.92%, and healthcare 1.33%. This positive market backdrop is the clearest available context, but does not establish a specific catalyst for the shares.